Zai Lab

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zai Lab and other ETFs, options, and stocks.

About ZLAB

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. 

CEO
Ying Du
CEOYing Du
Employees
1,784
Employees1,784
Headquarters
Shanghai, Shanghai
HeadquartersShanghai, Shanghai
Founded
2014
Founded2014
Employees
1,784
Employees1,784

ZLAB Key Statistics

Market cap
3.19B
Market cap3.19B
Price-Earnings ratio
-13.76
Price-Earnings ratio-13.76
Dividend yield
—
Dividend yield—
Average volume
1.35M
Average volume1.35M
High today
$26.77
High today$26.77
Low today
$23.43
Low today$23.43
Open price
$25.75
Open price$25.75
Volume
1.22M
Volume1.22M
52 Week high
$29.02
52 Week high$29.02
52 Week low
$15.96
52 Week low$15.96

ZLAB News

Benzinga 1d
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing

Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an invest...

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
TipRanks 2d
Zai Lab presents first-in-human data from ZL-1503 Phase 1/1b trial

Zai Lab (ZLAB) announced preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally dis...

Simply Wall St 5d
Is Zai Lab A Bargain After New Trial Data And Fresh Funding?

Zai Lab (ZLAB) is back on investors’ screens after fresh Phase 1 data for its lead cancer drug, new funding, and third quarter 2026 results that outlined a pack...

Is Zai Lab A Bargain After New Trial Data And Fresh Funding?

Analyst ratings

83%

of 12 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More ZLAB News

Simply Wall St 6d
Early Trial Data Might Change The Case For Zai Lab Stock

Zai Lab reported Q3 2026 revenue of US$108.21 million and a net loss of US$46.14 million, while early data for lead cancer drug zoci and other pipeline updates...

Early Trial Data Might Change The Case For Zai Lab Stock

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.